"CORONAVIRUS INFO: Penn Medicine is dedicated to the health and safety of patients, their families, and our staff. Please visit our website for COVID-19 updates, including coronavirus FAQs, our visitation policy, and drive-thru testing."

During the past decade, Scheie Eye Institute conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 15 clinical trials were completed, i.e. on average, 65.2% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 8 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Scheie Eye Institute" #1 sponsor was "Jaeb Center for Health Research" with 9 trials, followed by "University of Pennsylvania" with 6 trials sponsored, "JHSPH Center for Clinical Trials" with 3 trials sponsored, "National Eye Institute (NEI)" with 3 trials sponsored and "Bausch & Lomb Incorporated" with 3 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Scheie Eye Institute" #1 collaborator was "National Eye Institute (NEI)" with 16 trials as a collaborator, "Allergan" with 5 trials as a collaborator, "Genentech, Inc." with 4 trials as a collaborator, "Regeneron Pharmaceuticals" with 3 trials as a collaborator and "National Institutes of Health (NIH)" with 2 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Scheie Eye Institute" are "Diabetic Macular Edema" (8 trials), "Diabetic Retinopathy" (4 trials), "Geographic Atrophy" (4 trials), "Dry Eye" (3 trials) and "Macular Degeneration" (3 trials). Many other conditions were trialed in "Scheie Eye Institute" in a lesser frequency.

Most popular intervention types in "Scheie Eye Institute" are "Drug" (36 trials), "Procedure" (6 trials), "Device" (3 trials), "Other" (3 trials) and "Behavioral" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Deferred aflibercept" (2 trials), "Deferred laser" (2 trials), "Prompt aflibercept" (2 trials) and "QR-110" (2 trials). Other intervention names were less common.

The vast majority of trials in "Scheie Eye Institute" are 50 trials for "All" genders.

Currently, there are NaN active trials in "Scheie Eye Institute". 1 are not yet recruiting, 5 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 31 completed trials in Scheie Eye Institute, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Scheie Eye Institute, 10 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 3 trials that are defined as “Not Applicable".

Scheie Eye Institute has several departments that took part in Clinical trials: "Pennsylvania Oncology Hematology Associates" - 42 trials, "3401 Market Street, Suite 202" - 4 trials, "University of Pensylvania, Perelman Center for Advanced Medicine - Penn Neuroscience Center" - 2 trials, "Hospital of the University of Pennsylvania (Penn Heart and Vascular Center)" - 2 trials, "University of Pennsylvania, Pennsylvania Hospital Department of Neurology, 330 South 9Th Street" - 2 trials, "Penn Blood Disorder Center" - 2 trials, "Rodebaugh Diabetes Center, University of Pennsylvania" - 2 trials